Novoste's Beta-Cath
This article was originally published in The Gray Sheet
Executive Summary
Enrollment in the pivotal clinical trial of the radiation-based system for treatment of restenosis is expected to be complete by the end of the first quarter, President and CEO Thomas Weldon reports at a Jan. 11 session of the Hambrecht & Quist healthcare conference in San Francisco. As of Jan. 8, 881 patients were enrolled in the 1,100-patient study, which includes an eight-month patient follow-up period. "Our expectation is that we will do a filing for a PMA at the latest in Q1 2000," Weldon tells investors. Novoste also plans to finish enrollment by the end of the second quarter for a trial evaluating use of Beta-Cath for in-stent restenosis. As of Jan. 8, 144 of an anticipated 386 patients had been enrolled
You may also be interested in...
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.